Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients

Fig. 3

Pathologic changes and immunohistochemistry analysis of sarcoglycans in patients with sarcoglycanopathies. a HE staining showing no pathologic changes; (e, i, m) HE staining showing a dystrophic pattern in patients 13, 16, and 22; (bd) a normal control subject showing positive staining of the three sarcoglycans (score 1); (fh) a representative case of LGMD2D showing severe reduction of α-SG and β-SG expression (score 4) and slight reduction of γ-SG expression (score 2); (jl) a representative case of LGMD2D showing severe reduction of α-SG expression (score 4), no expression of β-SG (score 5), and reduction of γ-SG expression (score 3); and (np) a representative case of LGMD2E showing no expression of any of the three sarcoglycans (score 5). HE, Hematoxylin-eosin staining (200× magnification); SG, sarcoglycan (400× magnification)

Back to article page